JP2013529080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529080A5 JP2013529080A5 JP2013510643A JP2013510643A JP2013529080A5 JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5 JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5
- Authority
- JP
- Japan
- Prior art keywords
- dom7h
- seq
- variant
- variable domain
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34651910P | 2010-05-20 | 2010-05-20 | |
| US61/346,519 | 2010-05-20 | ||
| PCT/EP2011/058298 WO2011144751A1 (en) | 2010-05-20 | 2011-05-20 | Improved anti-serum albumin binding variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529080A JP2013529080A (ja) | 2013-07-18 |
| JP2013529080A5 true JP2013529080A5 (OSRAM) | 2014-07-03 |
Family
ID=44352234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510643A Pending JP2013529080A (ja) | 2010-05-20 | 2011-05-20 | 改良された抗血清アルブミン結合変異体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9040668B2 (OSRAM) |
| EP (1) | EP2571900A1 (OSRAM) |
| JP (1) | JP2013529080A (OSRAM) |
| KR (1) | KR20130109977A (OSRAM) |
| CN (1) | CN103003303A (OSRAM) |
| AU (1) | AU2011254559B2 (OSRAM) |
| BR (1) | BR112012029280A2 (OSRAM) |
| CA (1) | CA2799633A1 (OSRAM) |
| EA (1) | EA201291009A1 (OSRAM) |
| IL (1) | IL222802A0 (OSRAM) |
| MX (1) | MX2012013406A (OSRAM) |
| SG (1) | SG185437A1 (OSRAM) |
| WO (1) | WO2011144751A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| EP3974449A1 (en) * | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| EP3458034A4 (en) | 2016-05-18 | 2020-01-01 | ModernaTX, Inc. | POLYNUCLEOTIDES ENCODING RELAXIN |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2025021183A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海复宏汉霖生物医药有限公司 | 编码促肾上腺皮质激素的多核苷酸及其相关组合物和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| PT1737962E (pt) | 2004-03-24 | 2010-12-03 | Domantis Ltd | Sequência líder universal gas1 |
| KR20120133403A (ko) | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
| CA2589800A1 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| BRPI0812398A2 (pt) | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
| DE112008003232T5 (de) | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| AU2010215482B2 (en) * | 2009-02-19 | 2014-02-13 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| EA027866B1 (ru) * | 2009-02-19 | 2017-09-29 | Глэксо Груп Лимитед | Улучшенные связывающие сывороточный альбумин варианты |
| BRPI1008014A2 (pt) | 2009-02-19 | 2016-10-04 | Glaxo Group Ltd | domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro |
| UY32514A (es) * | 2009-03-27 | 2010-10-29 | Glaxo Group Ltd | FUSIONES Y CONJUGADOS DE UN FÁRMACO INSULINOTRÓPICO Y dAb CON SEMIVIDA SÉRICAS MEJORADAS |
| JP2012532619A (ja) | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法 |
| BR112012007374A2 (pt) * | 2009-09-30 | 2019-09-24 | Glaxo Group Ltd | composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante |
-
2011
- 2011-05-20 EA EA201291009A patent/EA201291009A1/ru unknown
- 2011-05-20 CN CN2011800351661A patent/CN103003303A/zh active Pending
- 2011-05-20 US US13/698,794 patent/US9040668B2/en not_active Expired - Fee Related
- 2011-05-20 AU AU2011254559A patent/AU2011254559B2/en not_active Ceased
- 2011-05-20 JP JP2013510643A patent/JP2013529080A/ja active Pending
- 2011-05-20 WO PCT/EP2011/058298 patent/WO2011144751A1/en not_active Ceased
- 2011-05-20 EP EP11720310A patent/EP2571900A1/en not_active Withdrawn
- 2011-05-20 BR BR112012029280A patent/BR112012029280A2/pt not_active IP Right Cessation
- 2011-05-20 CA CA2799633A patent/CA2799633A1/en not_active Abandoned
- 2011-05-20 SG SG2012081683A patent/SG185437A1/en unknown
- 2011-05-20 MX MX2012013406A patent/MX2012013406A/es not_active Application Discontinuation
- 2011-05-20 KR KR1020127033268A patent/KR20130109977A/ko not_active Withdrawn
-
2012
- 2012-11-01 IL IL222802A patent/IL222802A0/en unknown
-
2015
- 2015-04-21 US US14/691,913 patent/US20150284454A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529080A5 (OSRAM) | ||
| CN110191896B (zh) | 改进的血清白蛋白结合物 | |
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| CN110049997B (zh) | 改进的血清白蛋白结合免疫球蛋白单可变结构域 | |
| CN110461870B (zh) | 改进的血清白蛋白结合物 | |
| CN103619878B (zh) | 结合血清白蛋白的蛋白 | |
| JP2009545319A5 (OSRAM) | ||
| JP2017506075A5 (OSRAM) | ||
| JP2017527272A5 (OSRAM) | ||
| JP6333271B2 (ja) | ＩＬ−１βへの結合メンバー | |
| JP2014513953A5 (OSRAM) | ||
| JP2010502183A5 (OSRAM) | ||
| JP2013518853A (ja) | 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド | |
| CN108473564A (zh) | 改进的血清白蛋白结合剂 | |
| JP2018526989A5 (OSRAM) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| JP2009539349A5 (OSRAM) | ||
| JP2010533498A5 (OSRAM) | ||
| JP2020521458A5 (OSRAM) | ||
| JP2010535032A5 (OSRAM) | ||
| JP2009528828A5 (OSRAM) | ||
| EA034854B1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP2013543384A5 (OSRAM) | ||
| JP2015506945A5 (OSRAM) | ||
| CN105658236A (zh) | 抗体 |